Tesamorelin vs sermorelin at a glance
Tesamorelin and sermorelin are both synthetic analogues of human GHRH, and both stimulate the same pituitary receptor. Past that, they diverge. Sermorelin is the unmodified GHRH(1-29) fragment, the shortest sequence that keeps full biological activity. Tesamorelin keeps the entire 44-residue GHRH sequence and adds a trans-3-hexenoic acid group at the N-terminus, a modification built specifically to resist the enzyme that chews through native GHRH within minutes.
The table below lines up the numbers that actually separate them in the literature.
| Feature | Tesamorelin | Sermorelin |
|---|---|---|
| Backbone | Full GHRH(1-44) sequence plus N-terminal hexenoyl group | Native GHRH(1-29) fragment, unmodified |
| Plasma half-life | About 8 minutes after subcutaneous dosing | About 6.2 minutes intravenously for the unmodified parent sequence |
| Subcutaneous bioavailability | Under 4% | About 5.1% for the parent sequence |
| Trial dose studied | 2 mg subcutaneously once daily | 1 mcg/kg IV (diagnostic); 30 mcg/kg SC daily (pediatric treatment) |
| Population studied | Adults with HIV-associated lipodystrophy | Children with idiopathic growth hormone deficiency |
| FDA status | Approved and marketed as Egrifta SV | Approved in the 1990s as Geref, withdrawn from sale in 2008 |
Same receptor, different molecule
Both compounds bind the GHRH receptor on pituitary somatotroph cells and activate the same Gs-adenylyl cyclase-cAMP-PKA cascade, releasing growth hormone from stored secretory granules in pulses rather than as a sustained elevation. That shared mechanism is why both sit alongside compounds like CJC-1295 and ipamorelin in growth hormone secretagogue research.
Unmodified GHRH is degraded in plasma by dipeptidyl peptidase-4, which clips the Tyr-Ala bond at the N-terminus within minutes of exposure. Sermorelin carries that exact vulnerable sequence with no protection added. Tesamorelin's hexenoyl group sits at the same N-terminus and was chosen specifically to interfere with that cleavage, the entire rationale for building a 44-residue analogue rather than using the shorter native fragment.
Half-life and dose: why single-digit minutes still matter
A 1988 pharmacokinetic study in Peptides (Rafferty et al., rat model) measured the parent GHRH(1-29) sequence, the same backbone sermorelin uses, at an intravenous half-life of 6.2 minutes, with D-amino acid-substituted analogues falling in a 4.7 to 7.4 minute range and subcutaneous bioavailability near 5.1%. None of the structural changes tested slowed degradation meaningfully.
Tesamorelin's own FDA-approved label reports a mean elimination half-life of about 8 minutes after subcutaneous dosing, with bioavailability under 4%, a modest gain over the unmodified backbone. Compare that to CJC-1295's albumin-binding Drug Affinity Complex, which stretches a related GHRH backbone's half-life to days rather than minutes, and it is clear tesamorelin was engineered for enzyme resistance at the same daily dosing frequency, not for a once-weekly protocol. Both peptides in the literature are dosed once daily, with concentration and volume worked out per protocol using standard peptide dosing math.
The trial evidence: adult metabolic data vs pediatric growth data
Tesamorelin's clinical record comes from adult metabolic trials, detailed further in the site's tesamorelin research overview. The landmark study (Falutz et al. 2007, NEJM, n=412) randomized HIV-positive patients with abdominal fat accumulation to 2 mg subcutaneous tesamorelin or placebo for 26 weeks. Visceral fat fell 15.2% on treatment against a 5.0% increase on placebo, triglycerides dropped 50 mg/dL, and IGF-1 rose 81.0% versus a 5.0% decline on placebo (p<0.001), with no significant change in fasting glucose or insulin.
A later pooled analysis (Mangili et al. 2015, PLoS One, n=806) combined two Phase 3 trials, 543 tesamorelin patients against 263 on placebo over six months. The odds of reaching a visceral fat target below 140 cm² were 3.9 times greater on tesamorelin.
Sermorelin's evidence base, covered in more depth in the sermorelin research overview, is older and sits in a different population. A 1999 review in BioDrugs (Prakash and Goa) describes intravenous sermorelin at 1 mcg/kg bodyweight as a diagnostic test for growth hormone deficiency, with fewer false positives than other provocative tests of the era. For treatment, once-daily subcutaneous sermorelin at 30 mcg/kg, given at bedtime, produced sustained gains in height velocity over 12 to 36 months in prepubertal children with idiopathic growth hormone deficiency, though the review calls the effect more modest than direct somatropin replacement.
Neither dataset answers the other's question: tesamorelin has adult visceral fat and lipid outcomes, sermorelin has pediatric growth outcomes, and treating one as a substitute for the other would mean comparing different endpoints in different age groups.
Regulatory status: one still on the market, one discontinued
Tesamorelin is FDA-approved and marketed as Egrifta SV, indicated specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The label carries explicit limitations: it is not indicated for general weight loss, long-term cardiovascular safety has not been established, and there is no evidence it affects adherence to antiretroviral therapy.
Sermorelin's approval history runs through NDA 020443 under the brand Geref, cleared by the FDA in the 1990s for pediatric idiopathic growth hormone deficiency, then withdrawn from the US market by the manufacturer in 2008. A 2013 FDA determination (78 FR 14095) states plainly that Geref was not withdrawn for reasons of safety or effectiveness. No branded product has returned to market since, and compounded sermorelin sold today is a separate matter: it is not the FDA-reviewed Geref formulation the pediatric trials used, and compounded products do not go through the same approval process.
Handling considerations for research protocols
Both peptides arrive lyophilized and get reconstituted with bacteriostatic water before use, the same baseline covered in the site's reconstitution guide. What differs is storage between doses: a reconstituted solution degrades faster at room temperature than the lyophilized powder does, so both are typically reconstituted close to when they will be used rather than in one large batch. In a tropical research setting like Indonesia, where ambient heat and humidity run high most of the year, that means keeping reconstituted vials refrigerated and limiting bench time, per the general lyophilized peptide storage guidance for tropical climates.